Get started
Inhibikase Therapeutics, Inc.
Long

$IKT Long. Daily chart

31
IKT (Inhibikase Therapeutics) Long:

- On 06/16/2021 priced a public offering of 15 million common shares at $3 per share
- On 07/26/2021 received clearance to begin a Phase 1b extension study to evaluate its lead drug candidate IkT-148009 in Parkinson's patients.

- Unusual volume recently
- Bullish divergence with RSI
TradingAmok
Also on:
Fundamental AnalysisIKTOscillatorsStocksstocksignalsstockstobuystockstowatchstockstradingstocktradingVolume

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Fundamental AnalysisIKTOscillatorsStocksstocksignalsstockstobuystockstowatchstockstradingstocktradingVolume
TradingAmok
Also on:

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.